With our Aescuvest-Blog around the topic of crowdfunding we would like to keep you always up to date. Articles, current news and expert knowledge from the world of health, finance and on various developments in the healthcare sector, from crowdfunding to IPOs.
The future of digital diabetes management: The ESYSTA Pen 2.0
On achieving the 3-million-euro financing threshold, Emperra plans to start the development of the ESYSTA Pen 2.0. But why? How will it differ from the current ESYSTA Pen? And why is this such an important factor for Emperra's international growth? Find out the answers to these questions and more in the following article.
What do the studies say? The benefit of the ESYSTA System is clinically proven.
It is possibly the most pertinent question regarding the ESYSTA System: Is it beneficial? Or in more technical terms: Does using ESYSTA have a medical benefit for diabetes patients and if so, what is that benefit? These questions are not only at the forefront for patients, doctors and health insurance providers, Emperra, as the developer of the ESYSTA System, also wanted a straight answer.
A diabetes diary is the most important source of data for successful diabetes treatment. Diabetes patients are required to enter their values in these diaries daily, sometimes up to 6 times a day. Gaps, mistakes or errors can complicate treatment. Alarmingly, however, meticulously kept diabetes diaries are a rarity.
The benefits of digitalisation for the healthcare sector
Digitalisation is not an end in itself but instead is gaining more and more traction in all areas of life due to the sum of its benefits. This naturally also applies to the benefits for the healthcare sector: In this sector, digital technologies and products such as, e.g. Emperra's ESYSTA system have the potential to overcome the major challenges of the upcoming years and decades, including demographic change, the consistent increase of chronic diseases and insufficient access to healthcare in economically underdeveloped, rural areas.
Why the German Digital Healthcare Act (DVG) is triggering such major investments
Digitalisation has the potential to genuinely improve the provision of healthcare in Germany. However, until recently, the integration of digital solutions was possible to only a very limited extent due to the general parameters of the German healthcare system. The German Digital Healthcare Act (Digitale-Versorgung-Gesetz, DVG) has now created conditions that do justice to the dynamism of digital transformation and the speed of its processes.
Diabetes mellitus, and in particular type 2 diabetes, is becoming an affliction of global proportion. In 2006, the International Diabetes Federation (IDF) already referred to the issue as "THE epidemic of the 21st century". Unfortunately, this prediction has turned out to be virtually on point.
The last nine months have been a thrill for Surge-on Medical. Since the launch of our equity crowdfunding campaign in August 2019, the company has been focused on raising funds and getting in touch with investors across Europe, without losing sight of daily operations and preparations for the future.
Start-ups can now apply to receive up to €500,000 in co-investment from EIT Health in return for options. Through the new Start-up Rescue Instrument, EIT Health aims to alleviate the economic shock posed by the COVID-19 pandemic.